Jennifer S Mammen
Overview
Explore the profile of Jennifer S Mammen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
2288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abbey E, Nudotor R, Khalifa B, Canner J, Prokopowicz G, Steele K, et al.
Obesity (Silver Spring)
. 2024 Dec;
33(1):33-40.
PMID: 39638570
Objective: Obesity is an independent risk factor for chronic pain frequently treated with opioids. Our study investigated the effect of Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) on...
2.
3.
Adams R, Oh E, Yasar S, Lyketsos C, Mammen J
JAMA Intern Med
. 2023 Oct;
183(12):1324-1331.
PMID: 37870843
Importance: Thyroid hormone is among the most common prescriptions in the US and up to 20% may be overtreated. Endogenous hyperthyroidism may be a risk factor for dementia, but data...
4.
Gavigan C, Abbey E, McGready J, Simonsick E, Mammen J
Endocr Pract
. 2023 Jun;
29(8):612-617.
PMID: 37391043
Objective: As thyroid hormone metabolism slows with advancing age, treatment dosing requirements change. Guidelines recommend titration from a low starting dose for older adults with hypothyroidism while providing weight-based estimates...
5.
6.
Ibad H, Mammen J, Simonsick E, Kwoh C, Guermazi A, Demehri S
Front Aging
. 2023 Apr;
4:1150645.
PMID: 37114095
Hyperthyroidism is associated with lower lean body mass, as a result of catabolic actions of thyroid hormone. Therefore, higher thyroid hormone levels could be a factor in the development of...
7.
Kotwal A, Perlman J, Goldner W, Marr A, Mammen J
JCO Oncol Pract
. 2023 Apr;
19(7):395-402.
PMID: 37023383
Immune checkpoint inhibitors (ICPis) have proven extremely efficacious in cancer therapy but also lead to a plethora of immune-related adverse events (irAEs). The endocrine irAEs are not only quite common...
8.
Schneider B, Naidoo J, Santomasso B, Lacchetti C, Adkins S, Anadkat M, et al.
J Clin Oncol
. 2021 Nov;
39(36):4073-4126.
PMID: 34724392
Purpose: To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods: A multidisciplinary...
9.
Santomasso B, Nastoupil L, Adkins S, Lacchetti C, Schneider B, Anadkat M, et al.
J Clin Oncol
. 2021 Nov;
39(35):3978-3992.
PMID: 34724386
Purpose: To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with chimeric antigen receptor (CAR) T-cell therapy. Methods: A...
10.
Flagg A, Rooper L, Sheth S, Shaear M, Santhanam P, Prescott J, et al.
Endocr Pract
. 2021 Jan;
26(7):754-760.
PMID: 33471644
Objective: Clinical practice for differentiated thyroid cancer is moving towards lobectomy rather than total thyroidectomy in patients at low risk of recurrence. However, recurrence risk assessment depends on post-operative findings,...